{"groups":[{"description":"35 mg/m\\^2/dose BID PO Dasatinib x 17 days\n\nIfosfamide, Carboplatin, Etoposide\n\nmicroarray analysis\n\nwestern blotting\n\nimmunohistochemistry staining method\n\nlaboratory biomarker analysis\n\ntherapeutic conventional surgery\n\nradiation therapy","id":"FG000","title":"Period 1: 35 mg/m^2 Dasatinib BID PO"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"6"}],"type":"Death"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"7"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"6"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Phase I of this study involved City of Hope patients, only. This protocol did not progress beyond Period 1: 35 mg/m\\^2/dose BID to other dose levels within Phase I. This protocol did not progress to Phase II, which would have involved other institutions. Sponsor withdrew support.","recruitmentDetails":"Phase I study participants were recruited based on physician referral at City of Hope Medical Center, between September 04, 2008 and February 04, 2010. Seven patients met the inclusion criteria and were enrolled on the study."}